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Patient Characteristics by Post-Cy Group
Characteristics Post-Transplant
Cyclophosphamide
P- value*
Yes No
n ¼ 21 % n ¼ 35 %
Age group (years)
0.1-9.9 17 81 26 74 .75
10.0-19 4 19 9 26
F. donor / M receptor 6 29 8 23 .90
Double cord 3 14 3 9 .66
Diagnoses
Acute leukemias 12 57 17 49
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166 S165matched sibling bone marrow transplantation results in
approximately 85% event free survival in high-risk patients
with Sickle Cell Disease (SCD) (Walters, NEJM, 2006).
However, this approach is limited by 5-10% transplant-
related mortality, 5-10% primary graft failure and the late
effects of Bu/CY. Alternate approaches include reduced
toxicity but more immunosuppressive conditioning and the
use of sibling cord blood (Geyer/Cairo, BJH, 2011 and Freed/
Cairo, BMT, 2012).
Objective: To determine the safety, donor chimerism and
long term organ function associated with Bu 12.8-16 mg/kg,
ﬂudarabine180 mg/m2 and alemtuzumab 54 mg/m2 (BFA)
reduced toxicity conditioning (RTC) prior to HLA-matched
sibling donor transplantation in pediatric recipients with
high risk SCD.
Methods: Patients 21 years of age with HbSS, HbSC, HbSb+
or HbSb0 were eligible if highly symptomatic (such as 2
vaso-occlusive crises per year requiring narcotics, acute chest
syndrome, stroke, retinopathy, splenic sequestration) and
with an HLA-matched sibling donor. Conditioning consisted
of busulfan (4mg/kg x 4d < 4 yrs and 12.8mg/ kg x 4d > 4
yrs), ﬂudarabine (30mg/m2 x 6d), and alemtuzumab (2mg/
m2 x 1d, 6mg/m2 x 2d, and 20mg/m2x 2d) as we have
described (Styczynski/Cairo,BMT,2011). All received tacroli-
mus and MMF as GVHD prophylaxis as we have described
(Bhatia/Cairo, BBMT, 2010).
Results: 12 patients (11M:1F), median age 12 (2-19) with
symptomatic SCD underwent sibling BM (n¼10) or CB (n¼2)
Allogeneic Stem Cell Transplantation (AlloSCT). Median
follow-up was 33 months. Median time to neutrophil and
platelet engraftment for recipients of sibling BM and CBwere
16 days (13-18), 18.5 days (9-43) and 39.5 days (38-41) and
74 days (73-75), respectively. The probability of grade II-IV
and grade III-IV aGVHD were 16.7% and 8.3%. No patients
developed cGVHD. Patients achieved mean whole-blood
donor chimerism of 85, 94, 93, 93, 89 and 93% and mean
erythroid (CD71) donor chimerism of 89, 89, 93, 90, 86, and
94% at days 30, 60, 100, 180, 365 and 730 post-transplant,
respectively. The Kaplan-Meier probability of OS and EFS was
100% (CI95: 73.5-100%). Neurological, pulmonary, vascular,
and splenic function were stable to improved at 2 years.
Conclusions: BFA (RTC) and HLA-matched sibling bone
marrow and cord blood AlloSCT in pediatric recipients
results in excellent EFS, long term donor chimerism, and
stable/improved organ function.SAA 3 14 8 23 .58
Others 6 29 10 29
RIC 7 33 16 46 .41
TBI 12 57 22 63 .78
ATG or Alemtuzumb 6 29 17 49 .17
HLA match (n¼52)
6/6 1 5 6 19
5/6 9 50 11 34 .31
4/6 10 45 15 47
Receptor CMV (+) 21 100 30 86 .14
CMV viremia 13 62 19 54 .78
Invasive mycosis 4 19 6 17 .99101
Post-Transplant Cyclophosphamide Is Feasible and
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Post-transplant Cyclophosphamide (Post-Cy) has demon-
strated to decrease the occurrence of aGVHD inpreclinical and
haploidentical studies. Nevertheless, Post-Cy increases time to
neutrophil recovery, an issue that is of utmost importance for
UCB transplant related mortality (TRM). We postulated that
despite UCB lower cellular doses, the use of Post-Cy decreases
graft vs host and host vs graft reactions, enhancing engraft-
ment, and improving clinical outcomes. So we explore the
feasibility of using Post-Cy in the setting of UCB trans-
plantation in children. In June/2010, our group decided to
include post-Cy for UCB transplantation. A single 50 mg/kg/
dose of Cywas addedonday +3. CSA andMMFwas started day+4, as well as G-CSF. Post-Cy was used both in RIC and mye-
loablative transplants. Rabbit ATG or Alemtuzumab was used
only for RIC transplants. The group that received Cy-Post (21
cases) was compared with our previous UCB transplantation
cases (35 cases) where Post-Cy was not used. Multivariate
logistic regression models were used to evaluate the inde-
pendence of the relationship between Cy-Post and aGvHD, of
other covariates such as, age, gender, RIC, HLA match, CMV
receptor status, pre-freezing TNC and CD34. Attached table
compares characteristics ofpatientswith andwithout Post-Cy.
No signiﬁcant differenceswere identiﬁed among the 2 groups.
The groupswith andwithout Post-Cywere infusedwith 7.1 vs
6.4x107 TNC/kg, and 2.84 vs 2.81x105 CD34+cells/kg, respec-
tively. 100-day (25% vs 26%) and 1-year (25% vs 31%) TRM and
overall survival (60% vs 57%) were not different among the
groups. Median time to neutrophil and platelet engraftment
with andwithout Post-Cywas24vs 16days (P< .01), and43vs
35 days (P¼0.02), respectively. Forty-nine (87.5%) patients
were evaluable for aGvHD, 49% were classiﬁed as grades II-IV.
In the group with Post-Cy grades II-IV aGvHD was 32%
comparedwith 68% in the groupwithout Post-Cy. ORwas 0.31
(95%CI:0.1, 1.0), and adjusted OR was 0.16 (95%CI: 0.03, 0.78),
P¼ .02. Nodocumented cases of grade IV aGvHD in thePost-Cy
group. In conclusion, we found an important effect of Post-Cy
over the occurrence of aGVHD, independently of HLA match,
and of other relevant variables. Neither, we ﬁnd an effect over
earlyTRM,and isuncertain its impactover long termmortality.
We hypothesize that usage of Post-Cy in UCB transplantation
in children, can allow the use of UCB units with greater HLA
mismatch, and thus, increasing the potential pool of grafts
available for transplantation. This couldbeespeciallyuseful for
ethnic minorities.* Fisher’s exact two sided test.102
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Historically, T cell-replete myeloablative BMT from HLA-
haploidentical donors demonstrated excessive rates of
severe graft-versus-host-disease (GVHD) and non-relapse
mortality (NRM). More promising results have recently
been demonstrated for adults with high-risk hematologic
malignancies using T cell-replete marrow and post-trans-
plantation cyclophosphamide (PT/Cy). Here, we report the
ﬁrst results using such an approach speciﬁcally for pedi-
atric patients. Our single-institution phase II clinical trial
initially enrolled subjects with refractory hematologic
malignancies, but later added high risk leukemias in
remission and chemosensitive lymphomas, to match
Children's Oncology Group BMT criteria. Conditioning
consisted of IV Busulfan (pharmacokinetically adjusted)
days e6 to e3 and Cy (50 mg/kg/day) days e2 and e1
except for patients with acute lymphocytic leukemia(ALL)
or lymphoblastic lymphoma(LL) who received Cy (50 mg/
kg/day) days e5 and e4 and total body irradiation (300cGy
/day) days e3 to 0. T-cell-replete bone marrow was used
for all patients. Postgrafting immunosuppression consisted
of Cy (50 mg/kg/day) days 3 and 4, followed by myco-
phenolate mofetil for 30 days and tacrolimus for 6 months.
Twelve patients were treated with a median age of 12
(range, 2-20). Diagnoses include acute myeloid leukemia (3
refractory, 3 CR2), ALL (1 primary refractory CR1, 2 CR2), 1
chronic myeloid leukemia in blast crisis, 1 chemosensitive
LL, and 1 chemosensitive mature B cell lymphoma. Two
patients had undergone prior myeloablative allogeneic
BMTs. Donor engraftment at Day 60 occurred in all
evaluable patients. Median time to engraftment of
neutrophils >500/mL was 26 days and platelets >20,000/mL
was 35 days. Cumulative incidences of acute GVHD grades
II-IV and grades III-IV at day 100 were 17% and 7%,
respectively, and chronic GVHD at 6 months was 42% with
all classiﬁed mild per NIH cGVHD consensus criteria. One
patient required systemic steroids for Grade 3 skin aGVHD
and responded completely. The cumulative incidence of
NRM at 100 days was 8% (1/12), with one death from
veno-occlusive disease in a patient who had received
gemtuzumab ozogamicin 3 weeks before BMT. No patients
with chemosensitive disease or in remission died from
transplant-related causes. With median follow-up of
surviving patients of 276 days (range 100e1015), actuarial
overall survival (OS) is 80% at one year. Of 8 patients with
chemosensitive disease or in remission, 2 have relapsed:
one primary refractory ALL and one multi-TKI resistant Ph+
ALL. For pediatric patients with high-risk hematologic
malignancies, HLA-haploidentical BMT with T cell replete
bone marrow and PT/Cy is associated with excellent rates
of engraftment, GVHD, OS, and NRM, similar to myeloa-
blative matched sibling BMT. It is therefore a feasibleTable 1
Graft N Regimen N C7
Protein
expression
Skin
Heal
UCB 5 MA 4 2 1
RIC 1 0 0
BM 13 MA 9 6 7y
RIC 4 1 3y
Total 18 18 10 11
* Deﬁned as a change from > 50% (before HCT) to < 10% (after HCT) skin covere
y Remarkably, signiﬁcant clinical improvement can be achieved even in the abs
z Approximately 30% of wild-type levels of C7 are believed to be sufﬁcient to proption for high risk pediatric patients who lack timely
access to an HLA-matched donor.103
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Recessive dystrophic epidermolysis bullosa (RDEB), an
incurable blistering genodermatosis, is due to deﬁciency of
type VII collagen (C7) resulting in lack of attachment
between the epidermis and dermis, a poor quality of life,
and early death. Between 2007 and 2012, 18 patients with
severe generalized RDEB have undergone allogeneic HCT at
the University of Minnesota. Thirteen patients were treated
with a myeloablative (MA) conditioning (busulfan IV with
pharmacokinetic targeting 1,000 mmol/min for the area
under curve; ﬂudarabine [FLU] IV 75 mg/m2, and cyclo-
phosphamide [CY] IV 200 mg/kg); 5 patients were treated
with non-MA conditioning (CY IV 50 mg/kg, FLU IV 200
mg/m2, anti-thymocyte globulin IV 90 mg/kg, and total
body irradiation 200 cGy) with cyclosporine A and myco-
phenolate mofetil as GVHD prophylaxis. Patients were
transplanted with bone marrow (BM) from an HLA-
matched sibling (n¼10) or HLA-matched unrelated donor
(n¼3), or partially matched umbilical cord blood (UCB,
n¼5). The primary endpoint of the analysis was survival
with skin improvement. Importantly, non-MA conditioning
was well tolerated, with a marked reduction in risk of
infection, and pulmonary and renal toxicity. Thus far, for
the entire cohort, the overall probability of survival is 73%
(95% CI, 49-96%) with 11 demonstrating partial to marked
biochemical and clinical improvement in mucocutaneous
disease on the basis of protein expression and resistance to
blistering. Transplant outcomes are shown in the Table 1.
We conclude that BM is the preferred source of HSC (alive
and engrafted: 11 of 13 [85%] with BM versus 1 of 5 with
CB [20%], P-value ¼ .02) and that early results with the
non-MA conditioning are promising in terms of toxicity
proﬁle and engraftment. Overall, HCT has the potential of
being a durable, systemic therapy for many people with
different forms and severities of EB, and sets the stage for
using BM cells in the treatment of a broad spectrum of
extracellular matrix disorders.ing*
Skin
chimerism,
N (range)z
GvHD
acute/
chronic
Alive Alive
and
Engrafted
1 (11-30%) 1 / 1 2 1
0 0 / 0 1 0
7 (2-97%) 1 / 0 7 7
2 (3-23%) 0 / 0 4 4
10 2 / 1 14 11
d with blisters and erosions.
ence of any detectable C7 early after HCT.
otect from extensive blistering.
